- Home
- NSIT vs DNLI Comparison
NSIT vs DNLI Comparison
Compare NSIT & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NSIT | DNLI |
|---|---|---|
| Founded | 1988 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.6B |
| IPO Year | 1995 | 2017 |
Fundamental Metrics
Financial Performance| Metric | NSIT | DNLI |
|---|---|---|
| Price | $83.68 | $15.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | ★ $118.75 | $32.18 |
| AVG Volume (30 Days) | 396.0K | ★ 1.7M |
| Earning Date | 02-05-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.21 | N/A |
| Revenue | ★ $8,271,548,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.57 | $3,973.10 |
| P/E Ratio | $19.35 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $77.10 | $10.57 |
| 52 Week High | $181.92 | $24.35 |
Technical Indicators
Market Signals| Indicator | NSIT | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 46.91 | 36.65 |
| Support Level | $81.45 | $16.66 |
| Resistance Level | $84.68 | $17.85 |
| Average True Range (ATR) | 2.54 | 0.66 |
| MACD | 0.79 | -0.21 |
| Stochastic Oscillator | 71.69 | 0.38 |
Price Performance
Historical ComparisonAbout NSIT Insight Enterprises Inc.
Insight Enterprises Inc is a Fortune IT provider engaged in helping businesses of all sizes, large enterprises, governments, schools, and healthcare organizations. The company has three geographic operating segments: North America, EMEA, and APAC. It generates maximum revenue from the North America segment. The company provides digital innovation, cloud/data center transformation, connected workforce, and supply chain optimization solutions and services.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.